相关实验视频

Updated: May 20, 2025

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

新型的复合物具有抗癌活性,可对抗耐辐射的肺腺癌细胞

Hao Wang¹, Guozhu Ren², Yue Xu²

¹School of Materials Science and Engineering, Jilin Jianzhu University, Changchun 130118, China.

Journal of inorganic biochemistry

|March 25, 2025

概括

一种新型的复合物Er ((acac) TPP,对抗抗辐射耐药的肺癌细胞具有显著的抗癌活性. 与西斯普拉丁相比,这种化合物显示出更高的疗效和更低的毒性,使其成为一个有前途的化疗候选者.

科学领域:

材料科学材料科学材料科学
生物化学生化学
在瘤学瘤学.

背景情况:

肺腺癌,特别是抗辐射 (RR) 非小细胞肺癌 (NSCLC),是一个重要的治疗挑战.
目前的治疗方法往往对RR-NSCLC的疗效有限,并具有显著的副作用.

研究的目的:

合成和评估一种新型的复合物,Er(acac) TPP,其对抗NSCLC和RR-NSCLC细胞的抗癌潜力.
为了比较Er(acac) TPP与标准化疗剂Cisplatin的疗效和毒性.

主要方法:

实验证实Er3+对NSCLC和RR-NSCLC细胞的抑制作用.
新型复合物的合成和净化:四甲林乙烯基酸 (Er(acac) TPP).
在体外评估Er(acac) TPP的疗效,细胞毒性,诱导亡,线粒体膜潜力 (MMP) 变化,活性氧物种 (ROS) 积累,Caspase-9水平和细胞循环停止 (G2/M).

主要成果:

与Er3+单独相比,Er(acac) TPP对NSCLC和RR-NSCLC细胞具有更强的抑制作用.
Er(acac) TPP对NSCLC-RR细胞的抑制效率明显高于西斯.
新型的复合体对正常细胞的毒性明显低于对癌细胞的毒性.
机理学研究表明,Er(acac) TPP诱导细胞亡,减少MMP,增加ROS,提升Caspase-9,并导致G2/M细胞循环停止.

结论:

Er(acac) TPP是一种新型的复合物,具有强大的抗癌活性,可对抗耐辐射肺腺癌.
与西斯普拉丁相比,其优越的疗效和改善的安全性状况将Er(acac) TPP定位为进一步开发化疗剂的有希望的候选药物.

关键词:

它具有抗癌活性.化学疗法药物化学疗法药物埃尔比复合物是一个复杂的物质.非小细胞肺癌是非小细胞肺癌.抗辐射细胞是具有耐辐射性的细胞.

更多相关视频

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

相关概念视频

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...